Edition:
India

Smith & Nephew PLC (SN.L)

SN.L on London Stock Exchange

1,450.50GBp
23 Apr 2019
Change (% chg)

6.00 (+0.42%)
Prev Close
1,444.50
Open
1,446.50
Day's High
1,451.50
Day's Low
1,441.50
Volume
52,234
Avg. Vol
2,267,025
52-wk High
1,548.50
52-wk Low
1,242.50

Latest Key Developments (Source: Significant Developments)

Smith & Nephew Completes Acquisition Of Leaf Healthcare
Wednesday, 17 Apr 2019 

April 17 (Reuters) - Smith & Nephew PLC ::SMITH & NEPHEW PLC - ACQUISITION.SMITH & NEPHEW PLC - COMPLETED ACQUISITION OF LEAF HEALTHCAR.  Full Article

Smith & Nephew Acquires Leaf Healthcare For Undisclosed Sum
Monday, 1 Apr 2019 

April 1 (Reuters) - Smith & Nephew PLC ::SMITH & NEPHEW PLC - ACQUISITION OF LEAF HEALTHCARE, INC..SMITH & NEPHEW PLC - COMMERCIAL TERMS HAVE NOT BEEN DISCLOSED..SMITH & NEPHEW - TO BUY LEAF HEALTHCARE, DEVELOPER OF LEAF PATIENT MONITORING SYSTEM FOR PRESSURE INJURY PREVENTION, PATIENT MOBILITY MONITORING.SMITH & NEPHEW PLC - TRANSACTION WILL BE FINANCED FROM EXISTING CASH AND DEBT FACILITIES.  Full Article

Smith & Nephew Acquires Brainlab Orthopaedic Joint Reconstruction Business
Wednesday, 13 Mar 2019 

Smith & Nephew PLC ::SMITH & NEPHEW ACQUIRES BRAINLAB ORTHOPAEDIC JOINT RECONSTRUCTION BUSINESS.SMITH & NEPHEW PLC - TRANSACTION INCLUDES CERTAIN INTANGIBLE ASSETS AS WELL AS ORTHOPAEDIC BRAINLAB SALESFORCE.SMITH & NEPHEW PLC - CO, BRAINLAB WILL COLLABORATE IN DEVELOPING APPLICATIONS IN ORTHOPAEDIC RECONSTRUCTION AND SPORTS MEDICINE.  Full Article

Osiris Therapeutics Says Co To Pay $18.7 Mln Termination Fee, If Deal Is Terminated - SEC Filing
Wednesday, 13 Mar 2019 

March 12 (Reuters) - Osiris Therapeutics Inc ::OSIRIS THERAPEUTICS INC - IF DEAL IS TERMINATED UNDER CERTAIN CIRCUMSTANCES CO TO PAY $18.7 MILLION TERMINATION FEE - SEC FILING.  Full Article

Smith & Nephew To Buy Osiris Therapeutics For $660 Mln
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Smith & Nephew PLC ::SMITH & NEPHEW TO ACQUIRE OSIRIS THERAPEUTICS, INC.PROPOSED DEAL FOR $19.00 PER SHARE IN CASH.DEAL FOR A TOTAL EQUITY VALUE OF APPROXIMATELY $660 MLN.OSIRIS' 360 EMPLOYEES ARE EXPECTED TO JOIN SMITH & NEPHEW ON COMPLETION.ACQUISITION WILL BE FINANCED FROM SMITH & NEPHEW'S EXISTING CASH AND DEBT FACILITIES.TRANSACTION IS EXPECTED TO BE ACCRETIVE TO SMITH & NEPHEW'S ADJUSTED EARNINGS PER SHARE FROM 2020.ACQUISITION IS EXPECTED TO GENERATE RETURN ON INVESTED CAPITAL THAT EXCEEDS CO'S COST OF CAPITAL IN THIRD YEAR AFTER CLOSING.PETER FRIEDLI TO COMMIT TO TENDER ABOUT 30% OUTSTANDING SHARES OF OSIRIS IN FAVOUR OF DEAL.UNDER TERMS OF DEAL, WILL COMMENCE 2-STEP TENDER OFFER TO PURCHASE ALL OUTSTANDING SHARES OF OSIRIS COMMON STOCK FOR $19/SHR IN CASH.  Full Article

Smith & Nephew Says Ian Barlow Will Retire As Senior Independent Director
Friday, 8 Feb 2019 

Feb 8 (Reuters) - Smith & Nephew PLC ::SMITH & NEPHEW PLC - IAN BARLOW WILL RETIRE AS SENIOR INDEPENDENT DIRECTOR.  Full Article

Smith & Nephew Qtrly Rev Up 1 Pct
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Smith & Nephew PLC ::QTRLY REVENUE $1,294 MILLION VERSUS $1,278 MILLION.FY REVENUE 4.904 BILLION USD VERSUS 4.765 BILLION USD YEAR AGO.SEES 2019 REVENUE EXPECTED TO INCREASE 2.5-3.5% UNDERLYING (AROUND 1.8-2.8% REPORTED).SEES 2019 TRADING PROFIT MARGIN EXPECTED IN 22.8-23.2% RANGE, A 40-80 BPS IMPROVEMENT EXCLUDING ONE-OFF 2018 LEGAL GAIN.FY EPS/ EPSA 76 CENTS.FY REPORTED REVENUE GROWTH OF 3% IS AFTER +1% FX IMPACT.FY FULL YEAR DIVIDEND UP 3% TO 36.0¢ PER SHARE.FY TRADING PROFIT MARGIN INCLUDES 50BPS BENEFIT FROM ONE-OFF LEGAL SETTLEMENT.TRADING PROFIT FOR YEAR WAS $1,123 MILLION (2017: $1,048 MILLION).DOES NOT BELIEVE UK'S DECISION TO LEAVE EU WILL HAVE SIGNIFICANT IMPACT ON LONG-TERM ABILITY TO CONDUCT BUSINESS INTO & OUT OF EU/UK.  Full Article

Smith & Nephew Announces U.S. Launch Of Pico 7 Single Use Negative Pressure Wound Therapy System
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Smith & Nephew PLC ::SMITH & NEPHEW ANNOUNCES US LAUNCH OF NEW PICO™ 7 SINGLE USE NEGATIVE PRESSURE WOUND THERAPY SYSTEM.  Full Article

U.S. FDA Approves Removal Of Boxed Warning From Smith & Nephew's REGRANEX Gel
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - Smith & Nephew PLC ::FDA APPROVES REMOVAL OF BOXED WARNING FROM REGRANEX◊ (BECAPLERMIN) GEL, 0.01% AS MULTIPLE STUDIES DEMONSTRATE PRODUCT SAFETY.U.S. FDA APPROVED REMOVING BOXED WARNING FOR HIGHER MORTALITY RATE SECONDARY TO MALIGNANCY FROM PRESCRIBING INFO OF REGRANEX GEL.  Full Article

Smith & Nephew Sees Corporate Tax Rate On Trading Results In 20-21 Pct Range From 2018
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Smith & Nephew Plc ::‍SMITH & NEPHEW UPDATE ON TAX​.‍AS RESULT OF US TAX CHANGE, FROM 2018 NOW EXPECTS A CORPORATE TAX RATE ON TRADING RESULTS IN RANGE 20% TO 21% FOR MEDIUM TERM​.‍EXPECT FULL YEAR TAX RATE ON 2017 TRADING RESULTS TO BE LOWER THAN OUR PREVIOUS GUIDANCE OF AROUND 22%​.‍THIS IS REDUCTION OF 4 TO 5 PERCENTAGE POINTS ON OUR PREVIOUS GUIDANCE OF AROUND 25%​.  Full Article

Deals of the day-Mergers and acquisitions

March 12 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday: